Read more to answer the following questions:
Evaluate the appropriate work up and treatment for HPV-related head and neck cancer
Analyze the interpretation and limitations of p16 staining as a surrogate marker for HPV
Identify the work up and treatment for a head and neck cancer of unknown primary
Welcome to Molecular Oncology Tumor Boards
The Molecular Oncology Tumor Boards are a series of bi-monthly, user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies. Moderated by an expert pathologist and medical oncologist, each case will be updated with new information over a 2-week period as user comments are added. Sign in with your ASCO username and password to participate. After 2 weeks, the discussion will be locked to further commentary and users will be able to claim CME credit for their participation. Visit ASCO University to learn more.
To participate in discussions on other oncology-related topics, visit ASCO’s member community on myConnection. Connect with colleagues, build your professional network, exchange ideas, collaborate, and more
Molecular Oncology Tumor Board
ASCO University
Aug 10, 2016 9:13 AM
28 Comments
Molecular Oncology Tumor Board
ASCO University
Jul 13, 2016 9:27 AM
Read more to answer the following questions:
According to WHO 2016 criteria, what is the most accurate diagnosis and how do we distinguish ET from PMF in era of molecular studies? Does it matter to distinguish early primary myelofibrosis from essential thrombocythemia for management?
How would we...
According to WHO 2016 criteria, what is the most accurate diagnosis and how do we distinguish ET from PMF in era of molecular studies? Does it matter to distinguish early primary myelofibrosis from essential thrombocythemia for management?
How would we...
Molecular Oncology Tumor Board
ASCO University
Jun 15, 2016 8:26 AM
Read more to answer the following questions: 1) What is the significance of the patient having only a partial resection of an ologodendroglioma? 2) What is the importance of the 1p19q co-deletion status of the tumor?
Molecular Oncology Tumor Board
ASCO University
May 11, 2016 9:46 AM
Read more to answer the following questions: 1) Would further imaging be required before discussing a plan for systemic therapy? 2) Which of the available tissue specimen/sites would be appropriate for HER2 testing: tissue from the primary resection specimen, metastasis from the para-aortic lymph...
Molecular Oncology Tumor Board
ASCO University
Apr 13, 2016 9:33 AM
Read more to answer the following questions: 1) What are available second line therapy options? 2) Do you test for PD-L1 prior to recommending therapy? 3) Does smoking history affect your treatment recommendations?
Pages
Advertisement